Medi­gene spins out AAV tech to a new biotech up­start in Swe­den

Ger­many’s Medi­gene AG is get­ting a new biotech start­up go­ing, out-li­cens­ing its AAV-like par­ti­cle tech to the new­ly mint­ed Swedish biotech com­pa­ny 2A Phar­ma AB, lo­cat­ed in Malmö, Swe­den.

Medi­gene says that it was work­ing on AAV par­ti­cle tech be­fore de­vot­ing it­self to T cells and im­munother­a­py. And now 2A Phar­ma plans to use it to de­vel­op new vac­cines, for can­cer as well as in­fec­tious dis­eases. And the up­start says it’s raised enough cash to take the biotech up to the clin­ic, though it did not spell out the de­tails on that score.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER